Lyrica refused European Marketing Approval

FibroAction has been informed that pharmaceutical giant Pfizer have been refused marketing approval for Lyrica as a treatment for Fibromyalgia Syndrome (Fibro) in Europe.

This follows the refusal of the European Medicines Agency (EMEA) to grant a marketing approval for Cymbalta as a treatment for Fibro in October 2008.

Currently, there are no treatments for Fibro which have European Marketing Approval.

More details to follow shortly.